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Abstract
Background: Recent evidence suggests that CD4
+CD25
+FoxP3
+ regulatory T-cells (Treg) may
be responsible for the failure of host anti-tumour immunity by suppressing cytotoxic T- cells. We
assessed the prognostic significance of tumour infiltrating lymphocytes (TIL) in intestinal-type
gastric cardiac cancer.
Methods: Tumour infiltrating lymphocyte (TIL) subsets and tumour infiltrating macrophages
(TIM) were investigated in 52 cases using tissue microarrays. The interrelationship between the cell
populations (CD3+, CD8+, CD20+, CD68+, GranzymeB+, FoxP3+) in different compartments
and NED-survival was investigated (median follow-up time: 61 months).
Results: Intraepithelial infiltration with TIL and TIM including Treg was generally low and not
related to NED-survival. However, patients with large numbers of FoxP3
+ Treg in the tumour
stroma (>125.9 FoxP3
+TILs/mm
2) had a median survival time of 58 months while those with low
FoxP3
+ TIL counts (<125.9 FoxP3
+TILs/mm
2)h a dam e d i a ns u r v i v a lt i m eo f3 2m o n t h s( p=0 . 0 0 6 ) .
Patients with high versus low stromal CD68
+/FoxP3
+ cell ratios in primary tumour displayed
median survivals of 32 and 55 months, respectively (p = 0.008).
Conclusion: Our results suggest that inflammatory processes within the tumour stroma of
gastric intestinal-type adenocarcinomas located at the gastric cardia may affect outcome in two
ways. Tumour-infiltrating macrophages are likely to promote carcinogenesis while large numbers of
Treg are associated with improved outcome probably by inhibiting local inflammatory processes
promoting carcinogenesis. Thus, inhibition of Treg may not be a feasible treatment option in gastric
adenocarcinoma.
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Gastric carcinoma is the third most common gastro-
intestinal tumour type in developed countries [1].
Similarities in risk-factors for adenocarcinoma of the
gastric cardia and the oesophagus [2] together with the
stable incidence of cardiac gastric cancer despite an
overall decline of gastric malignancies [3] suggest that
these tumours should be separated from distally located
gastric adenocarcinomas [4].
Escape from immunosurveillance is a fundamental step in
cancer development. There is accumulating evidence
indicating that CD4
+CD25
+FoxP3
+ regulatory T-cells
(Treg) are able to induce tolerance to self-antigens and
may also inhibit anti-tumour immune response. Tregs can
inhibit effector T-cells, suppress the antigen presenting
function and promote the immunosuppressive function
of dendritic cells, monocytes and macrophages [5,6].
The prognostic significance of tumour infiltrating lym-
phocytes (TIL) in cancer therapy is not fully understood.
A beneficial prognostic effect of increased lymphocyte
infiltration has been shown for various tumour types. In
ovarian carcinoma both intratumoural CD3
+ and CD8
+
TIL were associated with improved survival [7,8] while
Treg were identified as a significant negative prognostic
factor [9]. An inverse effect was observed in anal cancer
where low amounts of CD3
+ and cytotoxic TIL were
prognostically favourable, while Treg presence had no
influence on prognosis [10]. A recent investigation of
gastric malignancies found no correlation between the
number of Treg and patient survival, but emphasized the
significance of their distribution pattern [11].
We investigated the prognostic value of infiltration by
various TIL-subgroups and macrophages including Treg
in adenocarcinoma of the cardia in both primary tumour
and draining lymph nodes.
Methods
Patients
Between 1993 and 2004, 135 patients with gastric
adenocarcinoma of the cardia underwent evaluation
and primary surgical treatment at the Erlangen University
Hospital. A subgroup of 52 patients was enrolled in the
present study according to the following criteria: All
patients were required to have invasive gastric adenocar-
cinoma of the intestinal subtype according to the Laurén
classification without distant metastases at presentation.
Patients with oesophageal Barrett’s adenocarcinoma were
excluded. An exclusively surgical treatment regimen with
complete resection (R0) was performed. No patient
received (neo)adjuvant radiotherapy or chemotherapy.
Staging was recorded according to the International
Union against Cancer system (UICC 2002). We gathered
data concerning recurrence and survival both from our
university hospital, the patients’ physicians and the
respective residents registration office. The minimum
follow-up time was 36 months; the mean follow-up
time was 71.2 months (median 61.0 months) with a
95% confidence interval of 54.7 to 57.8 months. The use
of the tissue sections and the patients’ survival data
following patient consent was approved by the Frie-
drich-Alexander University Erlangen-Nuremberg ethics
committee.
Tissue microarray and immunohistochemistry
474 core biopsies from primary tumour, uninvolved
draining lymph nodes and, if applicable, metastatic
nodes were processed into tissue microarrays (TMA)
(Figure 1). As guide for microarray sampling, represen-
tative areas on standard H.E.-stained sections were
marked by an experienced GI-pathologist (A.D.). A
manual tissue arrayer (MTA-1, Beecher Instruments,
Inc., Sun Prairie, WI, USA) was used for TMA construc-
tion. From each marked region three 1.0 mm cores were
collected resulting in a total of six samples from the
primary tumour site, three samples from uninvolved
lymph nodes and three samples from metastatic lymph
nodes, respectively. Among patients with positive lymph
nodes, sufficient metastatic tissue for further processing
was available in 22 of 28 cases. The samples punched off
from the donor blocks were arrayed in a recipient
paraffin block. TMA slides were stained as described
before [10] using CD3, CD8, CD20, CD68, anti-
Granzyme B antibodies (all from Dako, Hamburg,
Germany), and a polyclonal anti-FoxP3 reagent
(Abcam, Cambridge, United Kingdom).
Quantification of TIL
Evaluation of the immunostained microarrays was
performed using a standard light microscope at a
magnification of ×200, a CCD-camera and a semi-
automatic image processing software (Biomas, Erlangen,
Germany). Labelled lymphocytes and macrophages were
counted. In each image surface areas of the epithelial
and the stromal compartments were calculated and
glandular luminal areas were subtracted. Thus, it was
possible to assess separately intraepithelial and stromal
lymphocyte and macrophage infiltration both in the
primary tumour site and lymphatic metastatic tissue
(Figure 1). For each case and immune cell subset six
images with most abundant infiltration were acquired
both of intraepithelial and stromal compartments
(mean total area per case determined for CD3: 0.466
mm
2, mean epithelial surface area per case: 0.241 mm
2,
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2). In
stromal tissue, only areas adjacent to tumour infiltration
were selected. In uninvolved lymph-nodes, two images
were acquired per core adding to a total of six images
per case.
Statistical Analysis
Clinical variables evaluated were age, gender, UICC
stage, T category and N category. Overall survival was
defined as the period from surgery until death or end of
follow-up. No-evidence-of-disease (NED) survival was
evaluated as the period from surgery until evidence of
recurrence (tumour recurrence, nodal recurrence or
distant metastases). A univariate regression analysis of
NED-survival was performed using Cox’s proportional
hazards model (SPSS, Chicago, IL, USA). For a multi-
variate analysis of NED-survival we adopted only
variables being of significant impact in univariate
analysis. Survival was analyzed by the Kaplan-Meier
method [12]. The log-rank test [13] was used to compare
survival curves between subgroups of patients. Median
values of TIL/TIM-infiltration were used as cut-off.
Results
Study group
The patients’ clinical and histological characteristics are
depicted in Tables 1 and 2. Overall survival and NED-
survival rates of the study group were 53.7% and 63.7%
at 5 years, respectively. Twelve patients died of unrelated
diseases. Median overall survival and NED-survival time
for all patients were 50 months (range, 46.4 - 70.8
months) and 41.5 months (range, 43.1 - 68.3 months),
respectively.
Distribution pattern of lymphocytes in gastric
adenocarcinoma
Due to the clear border between the stromal and
epithelial compartment in intestinal-type carcinomas,
we evaluated the two compartments separately. A
pronounced difference in TIL/TIM- infiltration between
these stromal compartments was detected both at
primary tumour site and in lymph node metastasis
(Table 3).
AllTILsubsetsandmacrophageswerefoundpredominantly
in stroma adjacent to epithelial tumour cell clusters while
they occurred only infrequently between epithelial cells
within the tumour cell nests (Figures 1 and 2).
The proportion of Tregs of total T cell counts was larger in
areas of tumour infiltration (tumour stroma, affected
lymph nodes) than in the control lymph nodes (Table 3).
Prognostic significance of tumour infiltrating lymphocytes
(TIL) and tumour infiltrating macrophages (TIM)
FoxP3
+ TIL infiltration of the tumour stroma at the
primary site was of pronounced prognostic significance:
patients with high stromal FoxP3
+ TIL counts (>125.9
FoxP
+ TIL/mm
2) had a median survival time of 58
months while those with low FoxP3
+ counts (<125.9
Figure 1
Tissue microarrays. (A) Tissue microarray, tumor
punches [TU], metastatic lymph node punches [LM] and
control lymph node punches stained for CD3. (B) Primary
tumor side. By means of a semi-automatic image processing
software (Biomas, Erlangen, Germany), the count of
positively stained cells was set into relation to the surface of
the epithelial compartment [EC] (after exclusion of the
luminal compartment [LC]) and the stromal compartment
[SC], respectively. (C) FoxP3
+ TILs in primary tumor site and
the stromal compartment (D) FoxP3
+ cells in the lymph
node (E) FoxP3
+ cells in control lymph node (F) CD3
+ TILs
in primary tumor site (G) CD8
+ TILs in primary tumor site
(H) CD20
+ TILs in primary tumor site (I) CD68
+
macrophages in primary tumor site (J) Granzyme B
+ TILs in
primary tumor site.
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2) had a median survival time of 32
months (hazard ratio = 0.23; C.I. 0.08 - 0.72; p = 0.006;
Figure 3C and Table 3). Considering the epithelial
compartment of the primary tumour site only, none of
the TIL subsets or macrophages had significant prog-
nostic impact on NED-survival.
In multivariate analysis including stromal FoxP3
+ TIL,
UICC-stage and nodal status, stromal Treg count was the
only independent significant variable with impact on
NED-survival (Table 4).
The ratio of stromal CD8
+ and FoxP3
+ cells was not
associated with significant differences in survival. How-
ever, the stromal CD68
+/FoxP3
+ cell ratio was of
prognostic significance (Table 4). In survival analysis,
patients with a high stromal CD68
+/FoxP3
+ cell ratio
(> 2.9) at the primary tumour site had a median survival
of 32 months while those with a lower CD68
+/FoxP3
+
cell ratio (< 2.9) had a median survival of 55 months
(p = 0.008) (graph not shown). Considering the
uninvolved regional lymph nodes alone, higher numbers
of Granzyme B
+ cells were linked to a beneficial outcome
(hazard ratio = 0.35; C.I. = 0.12 - 0.99; p = 0.05).
Correlation between TIL/TIM and clinical factors
Early disease (UICC stage I) was associated with
significantly better NED-survival rates compared to
advanced disease (UICC II-IV) (hazard ratio = 3.72; C.
I. = 1.07 - 12.08; p = 0.04). An increasing stromal FoxP3
+
TIL infiltration was inversely correlated with UICC-stage
(Pearson’s correlation coefficient, r = -0.40; p = 0.001),
number of lymph node metastases (r = -0.36; p = 0.009)
and N category in general (r = -0.36; p = 0.023). For
other cell types, no such correlation could be found.
Discussion
Tregs inhibit the function of effector cells [5,6]. Conse-
quently, an inhibitory effect of Treg on anti-tumour
immunity has been predicted. In agreement with this
hypothesis, large numbers of tumour-infiltrating Treg
were shown to be associated with poor outcome in
ovarian carcinomas [9]. However, studies of other
tumours have produced conflicting results. Thus, no
prognostic effect of Treg was observed in a study of anal
carcinomas [10]. In certain lymphomas, tumour-infil-
trating Treg were associated with favourable prognosis
[14]. A recent study of FoxP3
+ Treg in colorectal cancer
also showed high Treg numbers to be associated with
improved survival [15].
Studies on gastric carcinomas have also yielded conflict-
ing results. Kono et al. found a higher percentage of Treg
among PBMCs in patients with advanced gastric carci-
noma. Higher numbers of Treg in PBMCs had an adverse
effect on outcome, and numbers of Treg declined to
normal values following curative resection [16]. Mizu-
kami et al. found no effect of Treg counts on survival but
showed that a diffuse dissemination of Treg was
associated with poor survival while accumulation of
Treg in the peritumoural region correlated with a more
favourable outcome. But the former distribution pattern
was associated with diffuse gastric cancers while the
latter was predominantly found in intestinal type
carcinomas [11]. Kawaida et al. found that tumour
draining lymph nodes showed an increased prevalence
of CD4
+CD25
+ TIL as compared to control mesenteric
nodes. However, no specific correlation between survival
and intensity of Treg infiltration could be demonstrated
[17]. These previous studies have analyzed TIL numbers
in different compartments ranging from primary tumour
to PBMC, thus making comparison of results difficult.
Table 1: Patient characteristics: stage, grade and status
N( % )
Factor All patients 52 (100)
Gender Male 40 (76.9)
Female 12 (23.1)
TNM stage (UICC 2002) I 20 (39.2)
II 19 (36.5)
III 10 (19.2)
IV 3 (5.8)
Grading G 1 1 (2)
G 2 29 (56)
G 3 21 (40)
G4 1( 2 )
T category T 1 12 (23)
T 2 32 (62)
T 3 5 (10)
T4 3( 6 )
N category N 0 24 (46.2)
N + 28 (53.8)
N 1 22 (42.3)
N 2 6 (11.5)
Any Relapse Yes 17 (32.7)
No 35 (67.3)
Local recurrence Yes 5 (9.6)
No 47 (90.4)
Distant Metastasis Yes 14 (26.9)
No 38 (73.1)
Status Alive with NED 25 (48)
Dead of disease 15 (29)
Dead without disease 12 (23)
Table 2: Patient characteristics: follow-up and survival
Mean Median 95% C.I.
Age (years) 64.6 67.0 61.5 - 67.7
Follow-up time (months) 71.2 61.0 54.7 - 57.8
Overall survival time (months) 58.6 50.0 46.4 - 70.8
NED-survival time (months) 55.7 41.5 43.1 - 68.3
Time to relapse (months) 23.8 17.0 13.8 - 33.7
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morphologically homogeneous group of intestinal-type
adenocarcinomas located at the gastric cardia. We have
assessed the numbers of tumour-infiltrating immune
cells in different tumour-related compartments in rela-
tion to outcome parameters. We show firstly that the
presence of various TIL subsets including Treg, cytotoxic
T-cells as well as tumour-infiltrating macrophages within
the epithelial compartment had no significant influence
on survival rates. This is in contrast to our previous
analysis of anal carcinomas [10]. This may be attribu-
table to the differing growth patterns of the two tumour
entities with anal carcinomas growing in a more solid
fashion with less stromal support as compared to gastric
adenocarcinoma. We identified only two parameters
which were of prognostic significance. High numbers of
Treg in the tumour stroma at the primary site were
associated with improved prognosis while this was not
the case for other tumour-related compartments.
Furthermore, high numbers of macrophages in
combination with low numbers of Treg in the tumour
stroma indicated poor outcome. Moreover, we show that
the number of Tregs as a proportion of total T-cells is
higher in both in tumour stroma and in affected lymph
nodes as compared to uninvolved lymph nodes. This
enrichment of Tregs suggests that these cell are actively
recruited to the tumour site and points to a role for Tregs
in inhibiting local immune reactions by direct cell-to-cell
contact [18].
On the face of it, these findings are unexpected and
contrast previous studies of ovarian carcinoma [7-9,19].
Nevertheless, our findings parallel recent studies of Treg
in colorectal cancer [15]. It is important to keep in mind
that Treg exert their function via a direct membrane
contact mechanism [18]. This might explain the
observation that a larger proportion of T cells are
regulatory T cells both in the tumor stroma and the
affected lymph nodes as compared to the control lymph
nodes.
Table 3: Descriptive statistics for TILs and macrophages in the primary tumour, metastatic lymph nodes and non affected lymph nodes
for intraepithelial and stromal location
Cells per mm
2 Mean
Primary tumour Metastatic lymph node Uninvolved lymph node
epithelial stromal epithelial stromal lymphatic tissue
CD3 122.8 895.7 63.5 645.1 3710.1 7686.7
CD8 114.5 424.4 98.0 358.2 1071.9 2436.1
CD20 18.9 438.7 9.4 351.4 5612.7 n.d.
CD68 18.7 482.7 17.9 617.1 1457.8 506.4
FoxP3 14.3 187.5 12.1 90.2 532.0 337.0
Gran.B 3.0 39.8 0.8 42.3 89.4 46.9
Cells per mm
2 95% confidence interval of mean
Primary tumour Metastatic lymph node Uninvolved lymph node
epithelial stromal epithelial stromal lymphatic tissue
CD3 71.2 - 174.5 714.6 - 1076.8 3.7 - 123.3 389.4 - 900.9 3149.5 - 4270.7 7088.1 - 8285.4
CD8 51.1 - 178.0 299.6 - 549.2 0 (-35.3) - 231.3 146.2 - 570.3 696.9 - 1447.0 2203.2 - 2669.0
CD20 0 (-0.1) - 37.9 249.7 - 627.7 0 (-2.1) - 20.9 180.9 - 521.8 4800.7 - 6424.8 n.d.
CD68 12.5 - 24.9 407.6 - 557.7 2.2 - 33.6 388.6 - 845.6 1051.8 - 1863.9 451.5 - 561.4
FoxP3 6.5 - 22.2 142.0 - 233.0 5.7 - 18.5 51.5 - 128.8 179.3 - 884.7 256.2 - 417.7
Gran.B 0.6 - 5.4 28.3 - 51.2 0 - 1.7 21.4 - 63.2 17.7 - 161.1 32.8 - 61.0
Cells per mm
2 Median
Primary tumor Metastatic lymph node Uninvolved lymph node
epithelial stromal epithelial stromal lymphatic tissue
CD3 40.9 752.1 18.3 366.2 3625.3 7752.0
CD8 21.6 212.7 2.8 203.7 888.5 2433.4
CD20 0 146.7 0 242.8 5855.7 n.d.
CD68 11.5 480.9 2.3 487.5 1238.8 478.6
FoxP3 3.6 125.9 8.0 75.6 225.7 245.4
Gran.B 0 26.7 0 23.4 42.9 34.1
Numbers represent mean and median values for labelled cells per mm
2. In addition, 95% confidence intervals of the mean are given.
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Mean counts of TIL-subtypes in different compartments. The counts are given per mm
2.( A )C D 3
+ counts (B) CD8
+
counts (C) FoxP3
+ counts. The asterisks (*) indicate that a statistical significant difference (p < 0.001 level) was observed
between intraepithelial and stromal compartment of primary tumor and metastatic tissue of the lymph node, respectively, and
between affected and uninvolved lymph node.
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Prognostic significance of FoxP3
+ lymphocytes in gastric adenocarcinoma of the cardia.N E D - s u r v i v a lr a t e si n
relation to the TIL infiltration were calculated by the Kaplan-Meier method and analyzed by the log-rank test. (A) Distribution
of FoxP3
+ cell counts in stromal compartment of primary tumor. The abscissa shows the average number of intraepithelial
FoxP3
+ TILs while the ordinate depicts the number of cases in each class. (B) Impact of FoxP3
+ TILs in epithelial compartment
of primary tumor, (C) impact of FoxP3
+ TIL in stromal compartment of primary tumor, (D) impact of FoxP3
+ TILs in tumor
compartment of metastasis, (E) impact of FoxP3
+ TILs in stromal compartment of metastasis, (F) impact of FoxP3
+ cells in
lymph nodes.
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Univariate Analysis Multivariate Analysis
Variable Hazard ratio 95% C.I. P Hazard ratio 95% C.I. P
Age, years (continuous) 1.01 0.96-1.06 0.78 - - -
Gender (female [n = 12] vs male [n = 40]) 0.48 0.11-2.10 0.33 - - -
Stage (UICC II and higher [n = 32] vs. UICC I [n = 20]) 3.72 1.07-12.98 0.04 2.00 0.42-9.09 0.39
Grade (3+4 [n = 22] vs. 1+2 [n = 30]) 1.43 0.55-3.71 0.46 - - -
T category (T3/T4 [n = 8] vs. T1/T2 [n = 44]) 2.48 0.80-7.68 0.11 - - -
N category (. N+ [n = 28] vs N0 [n = 24]) 3.27 1.06-10.02 0.04 2.04 0.51-8.33 0.32
Number of metastatic lymph nodes (continuous) 1.35 1.17-1.56 <0.001 - - -
TILs and macrophages in primary tumour site (high vs. low)
Hazard ratio 95% C.I. P Hazard ratio 95% C.I. P
Intraepithelial
CD3+ TIL 0.76 0.29-1.98 0.58 - - -
CD8+ TIL 1.26 0.48-3.32 0.63 - - -
CD20+ TIL 2.05 0.79-5.32 0.14 - - -
CD68+ TIM 0.69 0.27-1.80 0.45 - - -
FoxP3+ TIL 0.78 0.30-2.03 0.61 - - -
Granzyme B+ TIL 0.72 0.21-2.53 0.61 - - -
Stromal -- -
CD3+ TIL 0.86 0.33-2.23 0.76 - - -
CD8+ TIL 0.85 0.33-2.20 0.74 - - -
CD20+ TIL 0.80 0.31-2.08 0.65 - - -
CD68+ TIM 0.81 0.31-2.10 0.66 - - -
FoxP3+ TIL 0.23 0.08-0.72 0.01 0.25 0.08-0.78 0.016
Granzyme B+ TIL 0.87 0.33-2.29 0.78 - - -
Ratio stromal CD68 (primary tumour)/stromal FoxP3 (primary tumour) 4.02 1.31-12.36 0.02
TIL and macrophages in metastatic tissue (high vs. low)
Intraepithelial Hazard ratio 95% C.I. P
CD3+ TIL 0.32 0.09-1.12 0.07
CD8+ TIL 1.14 0.35-3.76 0.83
CD20+ TIL 0.20 0.03-1.58 0.13
CD68+ TIM 0.96 0.29-3.16 0.95
FoxP3+ TIL 0.58 0.17-1.99 0.39
Granzyme B+ TIL 0.88 0.19-4.09 0.87
Stromal
CD3+ TIL 0.61 0.19-2.03 0.42
CD8+ TIL 1.16 0.35-3.81 0.81
CD20+ TIL 0.51 0.15-1.75 0.28
CD68+ TIM 1.30 0.40-4.28 0.66
FoxP3+ TIL 0.81 0.25-2.69 0.74
Granzyme B+ TIL 0.75 0.23-2.46 0.63
Lymphocytes and macrophages in uninvolved regional lymph node (high vs. low)
Hazard ratio 95% C.I. P
CD3+ 0.47 0.17-1.26 0.13
CD8+ 0.84 0.32-2.19 0.72
CD20+
CD68+ 0.56 0.21-1.47 0.24
FoxP3+ 1.03 0.40-2.68 0.95
Granzyme B+ 0.35 0.12-0.99 0.05
For multivariate Cox's proportional hazards model UICC-stage and nodal status were adopted as covariates. Median values were used as cut-off.
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or to autoimmune gastritis, is considered the major risk
factor for the development of gastric cancer of intestinal
type. This is probably also true for gastric adenocarcinoma
locatedat thecardia[20].Development of chronicH.pylori
gastritis and progression to gastric atrophy and preneoplas-
tic lesions has been shown to be associated with the
development of a Th1-predominant local immune reaction
in mouse experiments [21]. Thus, the presence of large
numbers of local Treg may well help to dampen these local
inflammatory responses. This notion is also supported by
the observation that gastric Treg can suppress H. pylori-
induced T cell proliferation and IFN-gamma production
[22]. It is speculated that Treg may inhibit local effector T-
cells contributing to gastric carcinogenesis. A possible
mechanism may be that the effect of Treg is mediated via
a down-regulation of harmful proinflammatory cytokines
known to promote malignancy [23-25]. The notion that
Treg may exert an inhibitory effect on gastric cancer
development is also in keeping with our observation that
Treg are particularly prevalent in earlier stages of gastric
carcinogenesis since any effect of these cells is likely to be
greatest at this time point. Nonetheless, further functional
studieswillbenecessarytoelucidatetheexactroleofTregin
gastric cancer. Moreover, there is the emerging concept that
not all FoxP3 positive cells might be natural Tregs with
stable FoxP3 expression. Natural Treg cells might be
detected by analyzing the Treg-cell specific demethylated
region (TSDR) in tissue specimen [26].
We also find that a higher number of Granzyme B
positive T cells in uninvolved lymph nodes is associated
with a better outcome. Granzyme B is a key cytolytic
mediator secreted by activated cytotoxic T cells. A large
systemic number of activated cytotoxic T cells as
represented by large numbers in uninvolved lymph
nodes may be an indicator of an efficient systemic host
anti-tumor immunity [27].
Moreover, we show that large numbers of tumour-
associated macrophages in conjunction with small
numbers of Treg are associated with poor prognosis.
This is in agreement with a previous study [28]. It is now
well accepted that tumour-associated macrophages
promote tumour development for example through
stimulating angiogenesis or modulating the plasticity
of extracellular matrix [29]. Moreover, it has been shown
recently that activated macrophages may activate Wnt
signalling in gastric cancer epithelial cells via TNF-alpha
thus contributing to tumour development [30].
Conclusion
Our results suggest that inflammatory processes within
the tumour stroma of intestinal-type adenocarcinoma of
the gastric cardia may affect outcome in two ways.
Tumour-infiltrating macrophages are likely to promote
carcinogenesis as has been reported previously for
various tumour models. By contrast, Treg may down-
modulate local inflammatory processes which promote
carcinogenesis. Thus, inhibition of Treg may not be a
feasible treatment option in gastric adenocarcinoma.
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